映恩生物-B(09606.HK)：DB-1303/BNT323用于HER2阳性不可切除或转移性乳腺癌患者的III期临床试验达到主要研究终点

Core Viewpoint - The company, InnoCare Pharma, has announced that its drug DB-1303/BNT323 has met the primary endpoint of progression-free survival (PFS) in a Phase III clinical trial for HER2-positive unresectable or metastatic breast cancer patients previously treated with trastuzumab and taxanes [1] Group 1 - The independent data monitoring committee (IDMC) evaluated the trial and confirmed the positive results compared to the control group [1] - The company plans to communicate with the National Medical Products Administration (NMPA) in China regarding the submission of a Biologics License Application (BLA) for DB-1303/BNT323 [1]